Shoubing Zhou
Hefei, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Igniting cold tumors: reprogramming the tumor immune microenvironment with dual-payload ADCs in combination with PD-L1&4-1BB bispecific antibodies.
Journal: Journal for immunotherapy of cancer
Published: May 20, 2026
Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.
Journal: BMJ (Clinical research ed.)
Published: March 16, 2026
Non-Armored GCC-targeting CAR-T cell therapy demonstrates significant efficacy in patients with advanced colorectal cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 02, 2026
Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study.
Journal: Experimental hematology & oncology
Published: December 23, 2025
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: November 14, 2025
Identification and validation of hub genes involved in papillary thyroid carcinoma progression.
Journal: BMC cancer
Published: October 18, 2025
Reprogramming the tumor microenvironment: synergistic mechanisms of antibody-drug conjugates and immune checkpoint inhibitors.
Journal: Antibody therapeutics
Published: June 10, 2025
Cancer stem cells in personalized therapy: mechanisms, microenvironment crosstalk, and therapeutic vulnerabilities.
Journal: Frontiers in cell and developmental biology
Published: April 28, 2025
Reprogramming the Tumor Immune Microenvironment with ICAM-1-Targeted Antibody‒Drug Conjugates and B7-H3-CD3 Bispecific Antibodies.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: November 26, 2024
FcRn-guided antigen trafficking enhances cancer vaccine efficacy.
Journal: Cancer immunology, immunotherapy : CII
Published: August 15, 2024
A bispecific antibody targeting the Ig domains of Siglec-E displays enhanced antitumor effects.
Journal: International journal of biological macromolecules
Published: August 14, 2024
Synergistic approach to combating triple-negative breast cancer: DDR1-targeted antibody-drug conjugate combined with pembrolizumab.
Journal: Journal of pharmaceutical analysis
Published: June 15, 2024
Last Updated: 09/26/2026